Navigation Links
Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
Date:3/13/2008

NEW YORK, March 13 /PRNewswire/ -- Biologics and derma fillers are driving significant growth in the prescription dermatological drug market, due in large part to new products and technology developments. The market was valued at $8.9 billion in 2006 and is expected to achieve a CAGR of 7% through 2011, lead by the anti-aging/photo-damage, hair treatment, psoriasis and skin cancer treatment segments, according to Kalorama Information's new report Prescription Dermatological Drugs: Worldwide Market, 6th Edition.

"There are impressive new options for the treatment of aging skin, acne, psoriasis and a host of other conditions -- including bio-engineered collagen, hydroxyapatite fillers and new biologic agents," notes Mary Ann Crandall, the author of the report. "These have moved from promising developments to viable treatment alternatives."

New fillers include bio-engineered human injectable collagen, replacing bovine collagen which was plagued with short-lived results and allergic reactions, as well as hyaluronic acid gel, a new non-animal soft tissue filler that was recently approved in the United States. For longer-lasting results there is the new filler hydroxyapatite with a methylcellulose vehicle and a recently approved permanent injectable called polymethylmethacrylate. A new medical grade form of silicone is also being studied to determine its safety and efficacy as a permanent filler.

With the advent of recombinant deoxyribonucleic acid technology and advances in microbiology and immunology, the biologics field is expanding rapidly and dermatology is a primary focus for the development of new agents. Biologics are expected to dominate the psoriasis market with a 70% market share by 2011, due to the introduction of several new biologic immune modulators. A number of other skin diseases are also good candidates for biologic therapy, namely atopic dermatitis and cutaneous T-cell lymphomas.

Kalorama Information's report Prescription Dermatological Drugs: Worldwide Market, 6th Edition discusses critical issues and trends and provides updated market information for 2001 to 2011. The information presented is the result of interviews conducted with over 45 industry executives and data gathered through secondary research. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Prescription-Dermatological-Drugs-139953 2/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramainformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
2. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
3. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
4. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
5. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
6. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
9. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, ... 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients at CTAD ...
(Date:11/30/2016)... ... 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates ... prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that ...
(Date:11/30/2016)... FRANCISCO , November 30, 2016 The global  HIV-1 ... 2025, growing at a CAGR of 1.4%. According to a new report by ... public health issues worldwide. Continue Reading ... ... , , ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):